ICL Group Ltd. Files 6-K for August 2024
Ticker: ICL · Form: 6-K · Filed: Aug 14, 2024 · CIK: 941221
Sentiment: neutral
Topics: regulatory-filing, 6-K, registration-statement
TL;DR
ICL Group Ltd. filed a 6-K, standard update for August, confirming 20-F annual reports.
AI Summary
ICL Group Ltd. filed a Form 6-K on August 14, 2024, to be incorporated by reference into its Form S-8 registration statement. The filing is for the month of August 2024 and indicates that ICL Group Ltd. files annual reports under Form 20-F. The company's principal executive office is located in Tel Aviv, Israel.
Why It Matters
This filing serves as an update for investors regarding ICL Group Ltd.'s reporting status and incorporation by reference into a registration statement, which is a standard regulatory procedure.
Risk Assessment
Risk Level: low — This filing is a routine administrative report and does not contain new financial or operational information that would typically impact risk.
Key Players & Entities
- ICL Group Ltd. (company) — Registrant
- August 14, 2024 (date) — Filing Date
- Form 6-K (document) — Filing Type
- Form S-8 (document) — Registration Statement
- Form 20-F (document) — Annual Report Form
- Tel Aviv, Israel (location) — Principal Executive Office Location
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a report of a foreign private issuer for the month of August 2024 and is being incorporated by reference into the registrant's registration statement on Form S-8.
Which form does ICL Group Ltd. use for its annual reports?
ICL Group Ltd. files its annual reports under cover of Form 20-F.
Where is ICL Group Ltd.'s principal executive office located?
ICL Group Ltd.'s principal executive office is located at Millennium Tower, 23 Aranha Street, P.O. Box 20245, Tel Aviv, 61202, Israel.
What is the Commission File Number for ICL Group Ltd.?
The Commission File Number for ICL Group Ltd. is 001-13742.
When was ICL Group Ltd. previously known as Israel Chemicals Ltd.?
ICL Group Ltd. was formerly known as Israel Chemicals Ltd., with a date of name change on March 14, 1995.
Filing Stats: 4,593 words · 18 min read · ~15 pages · Grade level 16.6 · Accepted 2024-08-14 06:01:10
Key Financial Figures
- $1.8 b — ter of sequential growth, with sales of $1.8 billion, operating income of $211 millio
- $211 million — s of $1.8 billion, operating income of $211 million and adjusted EBITDA of $377 million Ra
- $377 million — of $211 million and adjusted EBITDA of $377 million Raising guidance for specialties-drive
- $1.75 billion — June 30, 2024. Consolidated sales were $1.75 billion versus $1.87 billion in the prior year.
- $1.87 billion — lidated sales were $1.75 billion versus $1.87 billion in the prior year. Operating income was
- $211 m — in the prior year. Operating income was $211 million, with adjusted operating income o
- $225 m — lion, with adjusted operating income of $225 million, versus $300 million of operating
- $300 million — perating income of $225 million, versus $300 million of operating income in the second quart
- $441 million — Adjusted EBITDA was $377 million versus $441 million. Diluted earnings per share were $0.09,
- $0 — illion. Diluted earnings per share were $0.09, with adjusted diluted EPS of $0.10,
- $0.13 — h adjusted diluted EPS of $0.10, versus $0.13 in the second quarter of last year. "I
- $0.8 billion — ts specialties-driven EBITDA of between $0.8 billion to $1.0 billion, an increase from previ
- $1.0 b — riven EBITDA of between $0.8 billion to $1.0 billion, an increase from previous guidan
- $0.7 billion — , an increase from previous guidance of $0.7 billion to $0.9 billion, without any change to
- $0.9 b — om previous guidance of $0.7 billion to $0.9 billion, without any change to expected p
Filing Documents
- zk2431833.htm (6-K) — 1416KB
- bottom.jpg (GRAPHIC) — 2KB
- cover2.jpg (GRAPHIC) — 23KB
- cover.jpg (GRAPHIC) — 19KB
- down.jpg (GRAPHIC) — 1KB
- up.jpg (GRAPHIC) — 1KB
- 0001178913-24-002568.txt ( ) — 1479KB
financial statements. You should read such discussion together with our financial statements
financial statements. You should read such discussion together with our financial statements. ICL Group Limited Q2 2024 Results 4 Adjustments to Reported Operating and Net income (non-GAAP) 4-6/2024 4-6/2023 1-6/2024 1-6/2023 1-12/2023 $ millions $ millions $ millions $ millions $ millions Operating income 211 300 414 765 1,141 Charges related to the security situation in Israel (1) 14 - 26 - 14 Write-off of assets and provision for site closure (2) - - - 15 49 Provision for early retirement (3) - - - - 16 Legal proceedings (4) - - - - (2) Total adjustments to operating income 14 - 26 15 77 Adjusted operating income 225 300 440 780 1,218 Net income attributable to the shareholders of the Company 115 163 224 443 647 Total adjustments to operating income 14 - 26 15 77 Total tax adjustments (5) (3) - (6) (3) (9) Total adjusted net income - shareholders of the Company 126 163 244 455 715 (1) For 2024 and 2023, reflects charges relating to the security situation in Israel . (2) For 2023, reflects mainly a write-off of assets related to restructuring at certain sites, including site closures and facility modifications, as part of the Company's global efficiency plan. (3) For 2023, reflects provisions for early retirement, due to restructuring at certain sites, as part of the Company's global efficiency plan . (4) For 2023, reflects a reversal of a legal provision . (5) For 2024 and 2023, reflects the tax impact of adjustments made to operating income . ICL Group Limited Q2 2024 Results 5 Consolidated adjusted EBITDA and diluted adjusted Earnings Per Share for the periods of activity Calculation of adjusted EBITDA was made as follows: 4-6/2024 4-6/2023 1-6/2024 1-6/2023 1-12/2023 $ millions $ millions $ millions $ millions $ millions Net income 130 167 256 461 687 Financing expenses, net 33 49 68 93 168 Taxes on income 48 84 90 211 287 Less: